Finance

Dow rises for a fourth day, gains more than 100 points after J&J vaccine deal and Disney earnings

Stocks rose on Wednesday on the back of coronavirus vaccine hopes and strong earnings from Disney. However, gains were capped as July private payrolls data disappointed and lawmakers continued negotiations on a new virus stimulus package.

The Dow Jones Industrial Average gained 170 points, or 0.6%. The S&P 500 advanced 0.4% and the Nasdaq Composite advanced 0.2% to a record high.

Johnson & Johnson announced it struck a $1 billion deal with the U.S. government to manufacture 100 million doses of its coronavirus vaccine candidate if it proves successful. J&J shares jumped 1%.

Better-than-expected earnings from Disney also helped sentiment on Wall Street. The theme park and media giant earned a profit of 8 cents per share, while analysts expected a loss of 64 cents per share. Disney said it now has 100 million paid subscribers across its streaming services, which include Disney+, Hulu and ESPN+. 

Disney shares climbed 6%.

ADP payrolls data disappoints

ADP reported Wednesday that private payrolls in the U.S. increased by just 167,000 in July. That’s well below a Dow Jones estimate of 1 million and represents a tumble from the 4.314 million added in June. 

The ADP report is seen as a preview to the government’s monthly jobs report, which is forecast to show a gain of more than 1.2 million jobs’ 

The final read on July Services PMI will be released at 9:45 am ET. Economists polled by Dow Jones are expecting a read of 49.6, the same as June. Finally, the ISM nonmanufacturing survey is set to release at 10:00 ET. Economists estimate a red of 55, according to Dow Jones, down from June’s read of 57.1. 

Traders also grappled with continuing talks in Washington over a new coronavirus stimulus package. 

The White House and Democratic congressional leaders have reported some progress in the negotiations, but they remain apart on some issues.

“The bottom line is that if we do see real disappointment in stimulus or the vaccine, then a 10% correction is the likely best-case scenario, and it’ll come quickly,” said Tom Essaye of The Sevens Report, in a note. “We cannot be complacent.”

Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the world.

View Article Origin Here

Related Articles

Back to top button